Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Jeffrey Cheng, MD, PhDRaymond Cho, MD, PhD
Headshot of Raymond Cho
Raymond Cho

Description

Summary

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Details

This is a one-arm, open-label study to examine the effect of dupilumab. Dupilumab is a FDA-approved medication for the treatment of atopic dermatitis. This study will examine how dupilumab affects immune cells within atopic dermatitis skin lesions. Fifteen subjects with moderate to severe atopic dermatitis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict dupilumab treatment response.

Keywords

Atopic Dermatitis, Dermatitis, Dupilumab

Eligibility

You can join if…

Open to people ages 18 years and up

  1. 18 years of age or older
  2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

You CAN'T join if...

  1. Known pregnancy
  2. Known immunodeficiencies
  3. Known parasitic infection -

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientists at UCSF

  • Jeffrey Cheng, MD, PhD
  • Raymond Cho, MD, PhD
    Dr. Cho is a physician and geneticist who investigates the molecular basis of skin disease. With colleague Dr. Jeffrey Cheng, he co-leads the RashX initiative at UCSF, which develops high resolution molecular fingerprints to understand and treat unusual skin diseases.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05858619
Phase
Phase 4 Atopic Dermatitis (Eczema) Research Study
Study Type
Interventional
Participants
Expecting 15 study participants
Last Updated